Fish oil and chicoric acid combination protects better against palmitate-induced lipid accumulation via regulating AMPK-mediated SREBP-1/FAS and PPARα/UCP2 pathways

References

• AbuMweis, S., et al., 2018. Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials. Journal of human nutrition and dietetics: the official journal of the british dietetic association, 31 (1), 67–84.
   PubMed Web of Science ®Google Scholar
• Aguirre, L., et al., 2014. Effects of resveratrol and other polyphenols in hepatic steatosis. World journal of gastroenterology, 20 (23), 7366–7380.
   PubMed Web of Science ®Google Scholar
• Albracht-Schulte, K., et al., 2019. Eicosapentaenoic acid improves hepatic metabolism and reduces inflammation independent of obesity in high-fat-fed mice and in HepG2 cells. Nutrients, 11 (3), 599.
   PubMed Web of Science ®Google Scholar
• Baum, J.I., Carroll, T.G., and Shouse, S.A., 2017. Docosahexaenoic Acid (DHA), not leucine, may protect HepG2 cells from palmitate-induced non-alcoholic fatty liver disease. The FASEB journal, 31 (1_supplement), 1036–1037.
   Google Scholar
• Best, K.P., et al., 2016. Omega-3 long-chain PUFA intake during pregnancy and allergic disease outcomes in the offspring: a systematic review and meta-analysis of observational studies and randomized controlled trials. The American journal of clinical nutrition, 103 (1), 128–143.
   PubMed Web of Science ®Google Scholar
• Chalasani, N., et al., 2012. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology, 142 (7), 1592–1609.
   PubMed Web of Science ®Google Scholar
• Chalasani, N., et al., 2018. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology, 67 (1), 328–357.
   PubMed Web of Science ®Google Scholar
• Chen, C., Yu, X., and Shao, S., 2015. Effects of omega-3 fatty acid supplementation on glucose control and lipid levels in type 2 diabetes: a meta-analysis. PLoS One, 10 (10), e0139565.
   PubMed Web of Science ®Google Scholar
• Chen, G.-C., et al., 2016. N-3 long-chain polyunsaturated fatty acids and risk of all-cause mortality among general populations: a meta-analysis. Scientific reports, 6, 28165.
   PubMed Web of Science ®Google Scholar
• Chen, L-h., et al., 2018. Omega-3 fatty acids as a treatment for non-alcoholic fatty liver disease in children: a systematic review and meta-analysis of randomized controlled trials. Clinical nutrition, 37 (2), 516–521.
   PubMed Web of Science ®Google Scholar
• Del Ben, M., et al., 2014. Modern approach to the clinical management of non-alcoholic fatty liver disease. World journal of gastroenterology, 20 (26), 8341–8350.
   PubMed Web of Science ®Google Scholar
• Dihingia, A., et al., 2018. Hexane-Isopropanolic Extract of Tungrymbai, a North-East Indian fermented soybean food prevents hepatic steatosis via regulating AMPK-mediated SREBP/FAS/ACC/HMGCR and PPARα/CPT1A/UCP2 pathways. Scientific reports, 8 (1), 1–12.
   PubMedGoogle Scholar
• Dihingia, A., et al., 2018. Hexane-isopropanolic extract of Tungrymbai, a North-East Indian fermented soybean food prevents hepatic steatosis via regulating AMPK-mediated SREBP/FAS/ACC/HMGCR and PPARα/CPT1A/UCP2 pathways. Scientific reports, 8 (1), 10021.
   PubMedGoogle Scholar
• Flaig, T.W., et al., 2007. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. International journal of cancer, 120 (9), 2028–2033.
   PubMed Web of Science ®Google Scholar
• Ge, Z., et al., 2015. Erythropoietin alleviates hepatic insulin resistance via PPARγ-dependent AKT activation. Scientific reports, 5, 17878.
   PubMed Web of Science ®Google Scholar
• Guo, R., et al., 2018. Cichoric acid prevents free-fatty-acid-induced lipid metabolism disorders via regulating Bmal1 in HepG2 cells. Journal of agricultural and food chemistry, 66 (37), 9667–9678.
   PubMed Web of Science ®Google Scholar
• Hawley, S.A., et al., 2010. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell metabolism, 11 (6), 554–565.
   PubMed Web of Science ®Google Scholar
• Hirsova, P., et al., 2016. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. Journal of lipid research, 57 (10), 1758–1770.
   PubMed Web of Science ®Google Scholar
• Kadowaki, T., et al., 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. The journal of clinical investigation, 116 (7), 1784–1792.
   PubMed Web of Science ®Google Scholar
• Kim, M., et al., 2017. Chicoric acid attenuate a nonalcoholic steatohepatitis by inhibiting key regulators of lipid metabolism, fibrosis, oxidation, and inflammation in mice with methionine and choline deficiency. Molecular nutrition & food research, 61 (5), 1600632.
   Web of Science ®Google Scholar
• Lee, J., and Scagel, C.F., 2013. Chicoric acid: chemistry, distribution, and production. Frontiers in chemistry, 1, 40.
   PubMed Web of Science ®Google Scholar
• Liao, C.C., et al., 2014. The inhibition of oleic acid induced hepatic lipogenesis and the promotion of lipolysis by caffeic acid via up-regulation of AMP-activated kinase. Journal of the science of food and agriculture, 94 (6), 1154–1162.
   PubMed Web of Science ®Google Scholar
• Liu, S.-H., et al., 2019. Omega-3 fatty acids-enriched fish oil activates AMPK/PGC-1α signaling and prevents obesity-related skeletal muscle wasting. Marine drugs, 17 (6), 380.
   PubMed Web of Science ®Google Scholar
• Lorente-Cebrián, S., et al., 2013. Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence. Journal of physiology and biochemistry, 69 (3), 633–651.
   PubMed Web of Science ®Google Scholar
• Luo, X., et al., 2012. Docosahexaenoic acid ameliorates palmitate-induced lipid accumulation and inflammation through repressing NLRC4 inflammasome activation in HepG2 cells. Nutrition & metabolism, 9 (1), 34.
   PubMedGoogle Scholar
• Miura, K., et al., 2016. Plasma eicosapentaenoic acid is negatively associated with all-cause mortality among men and women in a population-based prospective study. Nutrition Research, 36 (11), 1202–1209.
   PubMed Web of Science ®Google Scholar
• Mushtaq, M., and Wani, S., 2013. Polyphenols and human health–a review. International Journal of pharma and bio sciences, 4 (2), B338–B60.
   Google Scholar
• Nazari Soltan Ahmad, S., et al., 2018. Dunnione protects against experimental cisplatin-induced nephrotoxicity by modulating NQO1 and NAD + levels. Free radical research, 52 (7), 808–817.
   PubMed Web of Science ®Google Scholar
• Park, M.-J., et al., 2015. New role of irisin in hepatocytes: the protective effect of hepatic steatosis in vitro. Cellular signalling, 27 (9), 1831–1839.
   PubMed Web of Science ®Google Scholar
• Polyzos, S.A., et al., 2010. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes, obesity & metabolism, 12 (5), 365–383.
   PubMed Web of Science ®Google Scholar
• Ramírez-Zacarías, J.L., Castro-Muñozledo, F., and Kuri-Harcuch, W., 1992. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry, 97 (6), 493–497.
   PubMedGoogle Scholar
• Rashtchizadeh, N., et al., 2019. AMPK: a promising molecular target for combating cisplatin toxicities. Biochemical Pharmacology, 163, 94–100.
   PubMed Web of Science ®Google Scholar
• Robinson, W.E., et al., 1996. Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase. Proceedings of the national academy of sciences of the United States of America, 93 (13), 6326–6331.
   PubMed Web of Science ®Google Scholar
• Sadeghabadi, Z.A., et al., 2019. Palmitate-induced IL6 expression ameliorated by chicoric acid through AMPK and SIRT1-mediated pathway in the PBMCs of newly diagnosed type 2 diabetes patients and healthy subjects. Cytokine, 116, 106–114.
   PubMed Web of Science ®Google Scholar
• Salminen, A., and Kaarniranta, K., 2012. AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Research Reviews, 11 (2), 230–241.
   PubMed Web of Science ®Google Scholar
• Schlernitzauer, A., et al., 2013. Chicoric acid is an antioxidant molecule that stimulates AMP kinase pathway in L6 myotubes and extends lifespan in Caenorhabditis elegans. PLoS One, 8 (11), e78788.
   PubMed Web of Science ®Google Scholar
• St. George, A., et al., 2009. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology, 50 (1), 68–76.
   PubMed Web of Science ®Google Scholar
• Sumida, Y., and Yoneda, M., 2018. Current and future pharmacological therapies for NAFLD/NASH. Journal of gastroenterology, 53 (3), 362–376.
   PubMed Web of Science ®Google Scholar
• Tai, C.C., and Ding, S.T., 2010. N-3 polyunsaturated fatty acids regulate lipid metabolism through several inflammation mediators: mechanisms and implications for obesity prevention. The journal of nutritional biochemistry, 21 (5), 357–363.
   PubMed Web of Science ®Google Scholar
• Tilg, H., Moschen, A.R., and Roden, M., 2017. NAFLD and diabetes mellitus. Nature reviews. gastroenterology & hepatology, 14 (1), 32–42.
   PubMed Web of Science ®Google Scholar
• Turner, N., et al., 2008. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes, 57 (5), 1414–1418.
   PubMed Web of Science ®Google Scholar
• Wu, Y., et al., 2012. Activation of the AMP-activated protein kinase by eicosapentaenoic acid (EPA, 20:5 n-3) improves endothelial function in vivo. PLoS One, 7 (4), e35508.
   PubMed Web of Science ®Google Scholar
• Yang, J., et al., 2019. Oxidative stress and non-alcoholic fatty liver disease: effects of omega-3 fatty acid supplementation. Nutrients, 11 (4), 872.
   PubMed Web of Science ®Google Scholar
• Ziamajidi, N., et al., 2013. Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1. Food and chemical toxicology: an international journal published for the British industrial biological research association, 58, 198–209.
   PubMed Web of Science ®Google Scholar